GLP-1 and Compounded Peptides After the 2026 503A Shakeup: What Clinics Should Know

Few regulatory stories have touched concierge and longevity practices as directly as the rise and normalization of compounded GLP-1 medications. The compounding of these agents was possible in large part because of drug shortage status. As that status resolved and the FDA advanced its peptide category review, the ground shifted. Clinics that understood the mechanics adapted; those that treated shortage-era access as permanent were caught out.

Why Shortage Status Mattered So Much

Under federal law, compounders have more latitude to prepare a copy of an approved drug when that drug is on the FDA shortage list. The GLP-1 shortage created a window in which compounded versions were widely available. Once a drug is removed from the shortage list, that latitude narrows sharply, and compounding a copy of a commercially available, approved product becomes far more restricted.

A Dated Timeline Shows When Each Compounding Window Closed

Semaglutide entered the FDA shortage list in March 2022, and the agency declared a tirzepatide shortage in December 2022. With both drugs listed, 503A pharmacies and 503B outsourcing facilities could compound them. Brand-name prices above $1,000 per month drove broad demand for those compounded versions.

The FDA removed tirzepatide from the shortage list in late 2024 and semaglutide in February 2025. Those removals ended the shortage-based compounding authorization for both drugs. For semaglutide, 503A pharmacies had until April 2025 and 503B outsourcing facilities until 22 May 2025.

Safety Data Point to Oversight Quality as the Deciding Variable

A Binghamton University pharmacovigilance study in Expert Opinion on Drug Safety (April 2025) analyzed over 81,000 GLP-1 adverse event reports filed to FAERS between 2018 and 2024. Of those reports, 707 involved compounded products.

The study found elevated reporting odds ratios for product-quality events with compounded formulations compared with approved ones. Preparation errors reached an ROR of 48.92, contamination 19.00, and compounding or manufacturing issues 8.51.

A 2025 analysis in Missouri Medicine places the FDA concern on manufacturing variability and dosing inconsistency in lower-oversight settings. Its author, a quality assurance director at a 503B facility, points to sterility assurance, potency validation and API integrity as the controls that close that gap.

A 2025 retrospective report in the Journal of the American College of Clinical Pharmacy followed 50 patients on compounded semaglutide or tirzepatide in a clinical pharmacist-managed cardiometabolic clinic and reported weight and HbA1c reductions at 12 and 24 weeks. The authors concluded that the observations support compounded use under pharmacist supervision as an alternative during drug shortages. A 2025 study of a 153,000-patient primary care dataset examined how compounded GLP-1 prescribing is documented.

The Three Forces Acting on Peptide Compounding in 2026

• Shortage status: whether an approved product is on the FDA shortage list changes what may be compounded as a copy.
• The 503A vs 503B pathway: patient-specific compounding versus FDA-registered outsourcing carry different rules and documentation.
• The bulk drug substance category review: for peptides that are not simply copies of approved drugs, eligibility depends on the FDA’s ongoing evaluation.

How the Pieces Fit Together

A clinic evaluating a peptide in 2026 has to ask a short sequence of questions in the right order. Is this a copy of an approved, commercially available drug? If so, is that drug in shortage? If it is not a copy, is the bulk substance eligible under the current category framework, and through which pharmacy pathway? Skipping any step is how programs end up sourcing something they should not.

What This Means for a Concierge Program

• Do not build a membership offering on the assumption that shortage-era access is permanent. Reassess when shortage status changes.
• Confirm whether each product is a copy of an approved drug or a distinct bulk substance, because the rules diverge from there.
• Match the pharmacy pathway to the intended use and keep lot documentation, with the certificate of analysis available on request for each lot.
• Keep clinical decisions with the licensed prescriber and keep marketing free of disease-treatment claims for any compounded peptide.

Shortage-era access is a window, not a foundation. Build the program on documentation you can defend after the window closes.

Building a Program That Survives the Next Change

The clinics that navigated the GLP-1 transition well shared a habit: they documented the legal basis for every product they stocked and revisited it as conditions changed. That discipline is the same one the 2026 peptide category review rewards. A defensible program treats sourcing as a living process, tied to current FDA status, valid prescriptions, and verifiable documentation.